Research graph
References from Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome. Local targets link to admitted publications; unresolved targets remain external evidence.
Recommendations for the diagnosis and management of Prader-Willi syndrome
10.1210/jc.2008-0649 · 2008 · External reference
Nutritional phases in Prader-Willi syndrome
10.1093/acprof:oso/9780199398911.003.0016 · 2011 · External reference
Prader-Willi syndrome and early-onset morbid obesity NIH rare disease consortium: A review of natural history study
10.1007/978-1-4939-3474-4_88 · 2018 · External reference
Survival trends from the Prader-Willi Syndrome Association (USA) 40-year mortality survey
10.1038/gim.2017.92 · 2018 · External reference
The consequences of hyperphagia in people with Prader-Willi Syndrome: A systematic review of studies of morbidity and mortality
10.1016/j.ejmg.2021.104379 · 2022 · External reference
Prader-Willi syndrome: guidance for children and transition into adulthood
10.1530/ec-24-0091 · 2024 · External reference
Prader-willi syndrome
2026 · External reference
Prader-Willi syndrome: advances in genetics, pathophysiology and treatment
10.1016/j.tem.2003.11.003 · 2004 · External reference
Puzzle pieces: neural structure and function in prader-willi syndrome
10.3390/diseases3040382 · 2015 · External reference
Increased brain age in adults with Prader-Willi syndrome
10.1016/j.nicl.2019.101664 · 2019 · External reference
Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction
10.1016/s2213-8587(21)00002-4 · 2021 · External reference
Transcriptomics of the Prader-Willi syndrome hypothalamus
10.1016/b978-0-12-820683-6.00027-0 · 2021 · External reference
In vivo neuroimaging evidence of hypothalamic alteration in Prader-Willi syndrome
10.1093/braincomms/fcac229 · 2022 · External reference
The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood
10.1007/978-1-4939-3474-4_88 · 2010 · External reference
A review of psychiatric conceptions of mental and behavioural disorders in Prader-Willi syndrome
10.1016/j.neubiorev.2018.10.006 · 2018 · External reference
Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium
10.1186/s11689-021-09373-2 · 2021 · External reference
Assessment of hyperphagia in Prader-Willi syndrome
10.1176/ajp.155.9.1265 · 2007 · External reference
Prader-Willi Syndrome in children: Quality of life and caregiver burden
10.1111/apa.15738 · 2021 · External reference
Family matters: trauma and quality of life in family members of individuals with prader-willi syndrome
10.3389/fpsyt.2022.897138 · 2022 · External reference
Health state utilities associated with hyperphagia: Data for use in cost-utility models
10.1002/osp4.652 · 2023 · External reference
The impact of Prader-Willi syndrome on the family's quality of life and caregiving, and the unaffected siblings' psychosocial adjustment
10.1111/j.1365-2788.2012.01634.x · 2013 · External reference
Quality of life assessment in a sample of patients affected by Prader-Willi syndrome
10.1111/j.1440-1754.2007.01200.x · 2007 · External reference
High levels of caregiver burden in Prader-Willi syndrome
10.1371/journal.pone.0194655 · 2018 · External reference
Ageing in people with Prader-Willi syndrome: mortality in the UK population cohort and morbidity in an older sample of adults
10.1017/s0033291714001755 · 2015 · External reference
Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey
10.1038/gim.2016.178 · 2017 · External reference
Prader-willi syndrome - clinical genetics, diagnosis and treatment approaches: an update
10.2174/1573396315666190716120925 · 2019 · External reference
Metabolic and bariatric surgery for obesity in Prader Willi syndrome: systematic review and meta-analysis
10.1016/j.soard.2023.01.017 · 2023 · External reference
Physical health problems in adults with Prader-Willi syndrome
10.1002/ajmg.a.34171 · 2011 · External reference
Anxiety and depression symptomatology in adult siblings of individuals with different developmental disability diagnoses
10.1016/j.ridd.2015.12.017 · 2016 · External reference
Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review
10.1111/obr.12992 · 2020 · External reference
The pharmacological management of obesity in Prader-Willi syndrome: what does the future hold
10.1080/14656566.2026.2655969 · 2026 · External reference
Dietary management for adolescents with prader-willi syndrome
10.1093/acprof:oso/9780199398911.003.0016 · 2020 · External reference
Energy metabolism profile in individuals with prader-willi syndrome and implications for clinical management: A systematic review
10.3945/an.117.016253 · 2017 · External reference
Physical activity in patients with prader-willi syndrome-A systematic review of observational and interventional studies
10.3390/jcm10112528 · 2021 · External reference
The Italian National Survey for Prader-Willi syndrome: an epidemiologic study
10.1002/ajmg.a.32133 · 2008 · External reference
Variability and change over time of weight and BMI among adolescents and adults with Prader-Willi syndrome: a 6-month text-based observational study
10.1186/s13023-020-01504-7 · 2020 · External reference
Missed diagnoses and health problems in adults with prader-willi syndrome: recommendations for screening and treatment
10.1210/clinem/dgaa621 · 2020 · External reference
Physical exercise and Prader-Willi syndrome: A systematic review
10.1111/cen.13953 · 2019 · External reference
Body weight, behaviours of concern, and social contact in adults and adolescents with Prader-Willi syndrome in full-time care services: Findings from pooled international archival data
10.1186/s13023-024-03035-x · 2024 · External reference
Long-term weight control in adults with Prader-Willi syndrome living in residential hostels
10.1002/ajmg.a.62101 · 2021 · External reference
The use of growth hormone therapy in adults with Prader-Willi syndrome: A systematic review
10.1111/cen.14372 · 2021 · External reference
Review of growth hormone therapy in adolescents and young adults with Prader-Willi syndrome
10.1586/17446651.2015.1007126 · 2015 · External reference
Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study
10.1515/jpem-2013-0116 · 2014 · External reference
Clinical trials in prader-willi syndrome: A review
10.3390/ijms24032150 · 2023 · External reference
Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome
10.1016/j.ejmg.2010.09.015 · 2011 · External reference
Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial
10.1111/dom.13021 · 2017 · External reference
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
10.1371/journal.pone.0190849 · 2018 · External reference
Unresolved reference
External reference
The efficacy, safety, and pharmacology of a ghrelin O-acyltransferase inhibitor for the treatment of prader-willi syndrome
10.1210/clinem/dgac105 · 2022 · External reference
Unresolved reference
External reference
A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome
10.1002/ajmg.a.36653 · 2014 · External reference
Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial
10.1111/cen.13169 · 2016 · External reference
Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin
10.1111/cen.14387 · 2021 · External reference
Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome
10.1172/jci.insight.98333 · 2018 · External reference
Intranasal carbetocin reduces hyperphagia, anxiousness, and distress in prader-willi syndrome: CARE-PWS phase 3 trial
10.1210/clinem/dgad015 · 2023 · External reference
Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores in typically developing individuals and those with Prader-Willi syndrome
10.1038/s41598-023-48024-5 · 2023 · External reference
Diazoxide choline extended-release tablet in people with prader-willi syndrome: A double-blind, placebo-controlled trial
10.1210/clinem/dgad014 · 2023 · External reference
Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study
10.1186/s11689-024-09536-x · 2024 · External reference
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study
10.1002/oby.23928 · 2024 · External reference
Diazoxide choline extended-release tablets in Prader-Willi syndrome: A randomized, double-blind, withdrawal period study
10.1210/clinem/dgaf661 · 2026 · External reference
Critical analysis of bariatric procedures in Prader-Willi syndrome
10.1097/01.mpg.0000304458.30294.31 · 2008 · External reference
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects
10.2337/diabetes.52.2.380 · 2003 · External reference
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
10.3389/fendo.2024.1431292 · 2024 · External reference
Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity
10.1007/5584_2020_496 · 2021 · External reference
Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions
10.1038/s41430-024-01460-6 · 2024 · External reference
Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity
10.2337/dci24-0003 · 2024 · External reference
Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy
10.1007/s40263-014-0178-y · 2014 · External reference
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
10.1038/s42255-024-01113-9 · 2024 · External reference
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
10.3389/fnut.2024.1398059 · 2024 · External reference
Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy
10.1016/j.cell.2025.06.010 · 2025 · External reference
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021 · External reference
Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial
10.1001/jama.2021.1831 · 2021 · External reference
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial
10.1001/jama.2021.3224 · 2021 · External reference
Once-weekly semaglutide in adolescents with obesity
10.1530/ey.20.9.17 · 2022 · External reference
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
10.1038/s41591-022-02026-4 · 2022 · External reference
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
10.1016/s2213-8587(22)00008-0 · 2022 · External reference
Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial
10.1001/jama.2021.23619 · 2022 · External reference
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
10.1016/s0140-6736(21)00213-0 · 2021 · External reference
A revolution in obesity treatment
10.1038/s41591-023-02538-7 · 2023 · External reference
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes
10.1111/dom.14255 · 2021 · External reference
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
10.1002/oby.23673 · 2023 · External reference
Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial
10.1111/cob.12589 · 2023 · External reference
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials
10.1111/dom.15620 · 2024 · External reference
Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study
10.1016/j.orcp.2015.03.005 · 2015 · External reference
Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology
10.1002/oby.22653 · 2019 · External reference
Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study
10.1016/j.dsx.2020.03.009 · 2020 · External reference
Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study
10.1016/j.obpill.2023.100080 · 2023 · External reference
GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review
10.1016/j.jcte.2024.100333 · 2024 · External reference
A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
10.1177/1049731513507755 · 2023 · External reference
Incretin-based therapies for the treatment of binge eating - A systematic review
10.1002/phar.70135 · 2026 · External reference
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
10.1016/s2468-1253(24)00188-2 · 2024 · External reference
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
10.1038/s41366-025-01859-6 · 2025 · External reference
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
10.1111/dom.14551 · 2022 · External reference
Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist
10.1111/dom.70579 · 2026 · External reference
The benefits of GLP-1 drugs beyond obesity
10.1126/science.adn4128 · 2024 · External reference
Cardiometabolic profiles of oral and subcutaneous glucagon-like peptide-1 receptor mono-agonists in adults with overweight or obesity: A systematic review and network meta-analysis
10.1111/dom.70742 · 2026 · External reference
Renal outcomes of GLP-1 receptor agonists and tirzepatide across CKD stages and metabolic phenotypes (Type 2 diabetes and/or overweight/obesity): A scoping review
10.1007/s13300-026-01854-8 · 2026 · External reference
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
10.1056/nejmoa2413258 · 2025 · External reference
Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome
10.6065/apem.2020.25.1.52 · 2020 · External reference
Liraglutide therapy in Prader-Willi syndrome
10.1111/j.1464-5491.2011.03280.x · 2011 · External reference
The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome
10.1507/endocrj.ej12-0074 · 2012 · External reference
Liraglutide for weight management in children and adolescents with Prader-Willi syndrome and obesity
10.1210/clinem/dgac549 · 2022 · External reference
Effects of semaglutide on glycemic control and weight loss in a patient with Prader-Willi syndrome: a case report
10.1530/endoabs.81.ep254 · 2022 · External reference
Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi syndrome and type 2 diabetes
10.1016/j.endinu.2023.12.009 · 2024 · External reference
Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
10.3389/fendo.2024.1528457 · 2024 · External reference
Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
10.3389/fendo.2025.1533209 · 2025 · External reference
Semaglutide, a long-acting GLP-1 analogue, for the management of early-onset obesity due to MC4R defect: a case report
10.1159/000537921 · 2025 · External reference
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
10.1038/s41591-025-03913-2 · 2025 · External reference
Effectiveness of the dual GIP/GLP1-agonist tirzepatide in 2 cases of Alstrom syndrome, a rare obesity syndrome
10.1210/clinem/dgaf258 · 2025 · External reference
Effects of semaglutide on BMI and cardiometabolic profile in adolescents with variants in monogenic obesity-related genes
10.1210/jendso/bvaf149.041 · 2026 · External reference
Recommendations for real-world evidence of efficacy and safety of GLP-1 agonists in Prader-Willi syndrome: Report of a workshop held by the Foundation for Prader-Willi Research and International Prader Willi Syndrome Organisation
10.1111/dom.70282 · 2026 · External reference
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
10.1002/hep.21178 · 2006 · External reference
Validation of the Food Safe Zone questionnaire for families of individuals with Prader-Willi syndrome
10.1186/s11689-024-09589-y · 2025 · External reference
Heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists for weight loss in adults: a systematic review and meta-analysis
10.1001/jamainternmed.2025.8222 · 2026 · External reference
A review of nighttime eating disorders
10.1016/j.smrv.2008.07.005 · 2009 · External reference
Eating behavior and gastric emptying in adults with Prader-Willi syndrome
10.1159/000105447 · 2007 · External reference
Delayed gastric emptying in patients with Prader Willi syndrome
10.1515/jpem.2010.140 · 2010 · External reference
Acute idiopathic gastric dilatation with gastric necrosis in individuals with Prader-Willi syndrome
10.1002/(sici)1096-8628(19971231)73:4<437::aid-ajmg12>3.0.co;2-s · 1997 · External reference
Gastric rupture and necrosis in Prader-Willi syndrome
10.1097/mpg.0b013e31805b82b5 · 2007 · External reference
Gastric dilatation and abdominal compartment syndrome in a child with Prader-Willi syndrome
10.12659/ajcr.903608 · 2017 · External reference
Prader-Willi syndrome: consensus diagnostic criteria
10.1542/peds.91.2.398 · 1993 · External reference
Subclinical dysphagia in persons with Prader-Willi syndrome
10.1002/ajmg.a.38015 · 2017 · External reference
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
10.1093/ajcn/68.3.525 · 1998 · External reference
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
10.1152/ajpregu.1999.277.3.r910 · 1999 · External reference
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
10.1038/sj.ijo.0801627 · 2001 · External reference
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
10.1185/03007990802418851 · 2008 · External reference
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
10.1038/ijo.2013.162 · 2014 · External reference
Liraglutide effects on upper gastrointestinal investigations: implications prior to bariatric surgery
10.1007/s11695-018-3249-1 · 2018 · External reference
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
10.1016/j.jcjd.2016.08.101 · 2018 · External reference
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide
10.1007/s12630-023-02549-5 · 2023 · External reference
Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide
10.1016/j.cgh.2009.04.011 · 2024 · External reference
Mapping the effectiveness and risks of GLP-1 receptor agonists
10.1038/s41591-024-03412-w · 2025 · External reference
How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis
10.1111/obr.13916 · 2025 · External reference
Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial
10.1016/s2213-8587(25)00225-6 · 2025 · External reference
Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
10.1016/s2213-8587(25)00226-8 · 2025 · External reference
Tirzepatide as compared with semaglutide for the treatment of obesity
10.1056/nejmoa2416394 · 2025 · External reference
Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial
10.1056/nejmoa2301972 · 2023 · External reference
Coadministered cagrilintide and semaglutide in adults with overweight or obesity
10.1056/nejmoa2502081 · 2025 · External reference
Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
10.1056/nejmoa2502082 · 2025 · External reference
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
10.1016/s0140-6736(25)01185-7 · 2025 · External reference
